MX377481B - Derivados de serina como agonistas del receptor de grelina. - Google Patents

Derivados de serina como agonistas del receptor de grelina.

Info

Publication number
MX377481B
MX377481B MX2017001408A MX2017001408A MX377481B MX 377481 B MX377481 B MX 377481B MX 2017001408 A MX2017001408 A MX 2017001408A MX 2017001408 A MX2017001408 A MX 2017001408A MX 377481 B MX377481 B MX 377481B
Authority
MX
Mexico
Prior art keywords
ghrelin receptor
receptor agonists
receptor
serine derivatives
ghrelin
Prior art date
Application number
MX2017001408A
Other languages
English (en)
Other versions
MX2017001408A (es
Inventor
Kaoru Shimada
Keiko Obata
Kiyoshi Kawamura
Makiko Kuroda
Masaki Sudo
Nobuyuki Takahashi
Shinichi Koizumi
Yasuhiro Iwata
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of MX2017001408A publication Critical patent/MX2017001408A/es
Publication of MX377481B publication Critical patent/MX377481B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)

Abstract

La presente invención se relaciona con novedosos compuestos de fórmula (i) o una sal o solvato de éstos, farmacéuticamente aceptable, a procesos para su preparación, composiciones farmacéuticas que contienen los compuestos y a sus usos en terapia, por ejemplo, como moduladores del receptor secretagogo de hormona del crecimiento (también referido como el receptor de grelina o receptor GHSRIa) y/o para el tratamiento y/o profilaxis de un desorden mediado por el receptor de grelina. (ver Fórmula).
MX2017001408A 2014-08-05 2015-08-05 Derivados de serina como agonistas del receptor de grelina. MX377481B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462033369P 2014-08-05 2014-08-05
PCT/JP2015/003939 WO2016021191A1 (en) 2014-08-05 2015-08-05 Serine derivatives as ghrelin receptor agonists

Publications (2)

Publication Number Publication Date
MX2017001408A MX2017001408A (es) 2017-05-10
MX377481B true MX377481B (es) 2025-03-07

Family

ID=55263482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001408A MX377481B (es) 2014-08-05 2015-08-05 Derivados de serina como agonistas del receptor de grelina.

Country Status (11)

Country Link
US (1) US9873695B2 (es)
EP (1) EP3131916B1 (es)
JP (1) JP6051392B1 (es)
KR (1) KR101980180B1 (es)
CN (1) CN106459147B (es)
CA (1) CA2951619C (es)
ES (1) ES2707124T3 (es)
MX (1) MX377481B (es)
RU (1) RU2695649C2 (es)
TW (1) TWI724995B (es)
WO (1) WO2016021191A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108853147B (zh) * 2018-07-24 2021-12-24 苏州大学 一种缓释外泌体的多肽纳米纤维水凝胶及其制备方法与应用
WO2021085640A1 (ja) * 2019-10-31 2021-05-06 国立大学法人大阪大学 絶食を要する患者の筋肉量減少抑制剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
WO1994013696A1 (en) * 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
CN1174504A (zh) * 1993-11-09 1998-02-25 麦克公司 促进生长激素释放的哌啶、吡咯烷和六氢－1h－吖庚因
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA64751C2 (uk) * 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
MX2007008771A (es) * 2005-01-19 2007-09-11 Mgi Gp Inc Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp.
WO2006079077A2 (en) 2005-01-20 2006-07-27 Acadia Pharmaceuticals Inc. Use of diltiazem or analogs thereof as modulators of ghrelin receptor
WO2008129308A2 (en) * 2007-04-24 2008-10-30 Acacia Pharma Limited Drug combination and its use in the treatment of muscle loss
JP2013509434A (ja) 2009-10-30 2013-03-14 トランザイム・ファーマ，インコーポレイテッド 大環状グレリン受容体アンタゴニストおよびインバースアゴニストならびにその使用方法

Also Published As

Publication number Publication date
MX2017001408A (es) 2017-05-10
RU2017107028A3 (es) 2019-02-12
CA2951619C (en) 2023-01-10
US20170197961A1 (en) 2017-07-13
WO2016021191A1 (en) 2016-02-11
CN106459147B (zh) 2021-08-06
EP3131916A4 (en) 2017-03-15
ES2707124T3 (es) 2019-04-02
CN106459147A (zh) 2017-02-22
KR101980180B1 (ko) 2019-05-20
KR20170005862A (ko) 2017-01-16
EP3131916A1 (en) 2017-02-22
US9873695B2 (en) 2018-01-23
TW201613921A (en) 2016-04-16
RU2017107028A (ru) 2018-09-06
TWI724995B (zh) 2021-04-21
CA2951619A1 (en) 2016-02-11
EP3131916B1 (en) 2018-11-14
JP6051392B1 (ja) 2016-12-27
RU2695649C2 (ru) 2019-07-25
JP2017501966A (ja) 2017-01-19

Similar Documents

Publication Publication Date Title
JOP20210109A1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
MX382331B (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina útiles en el tratamiento del cáncer.
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
PH12017501191B1 (en) Quinazoline derivatives used to treat hiv
PH12017501057A1 (en) Substituted 2-anilinopyrimidine derivatives as egfr modulators
EA033281B1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
MX2018007319A (es) Imidazoquinolinas pegiladas como agonistas tlr7 y tlr8.
TW201613864A (en) Novel compounds
NZ733313A (en) Indole derivatives as dengue viral replication inhibitors
UY35334A (es) Compuestos y composiciones como degradantes selectivos del receptor de estrógeno
TW201613909A (en) Benzoxazinone amides as mineralocorticoid receptor modulators
NZ731118A (en) Dopamine d3 receptor antagonists compounds
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
CL2016000387A1 (es) Derivados de amida como antagonistas de ácido receptor lisofosfatidico
JOP20190183B1 (ar) معدِلات مستقبلات الاستروجين
MX376029B (es) Compuestos de isoindol.
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
MX379454B (es) Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases

Legal Events

Date Code Title Description
FG Grant or registration